Loading company…
ReEir develops regenerative medicine and cell therapy products.
Based in Tokyo, ReEir develops cell therapies intended to repair damaged tissue and address serious and chronic illnesses. Its treatments can be implemented through blood collection processes and are aimed at healthcare providers, hospitals, and clinics. Founded in 2017, the company was acquired by Hisamitsu Pharmaceutical Co., Inc. in December 2024. It was at the Seed stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in